Xentry-Gap 19
Alternative Names: XG19Latest Information Update: 18 Oct 2022
At a glance
- Originator OcuNexus Therapeutics
- Class Anti-ischaemics; Eye disorder therapies; Peptidomimetics; Vascular disorder therapies
- Mechanism of Action Connexin 43 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Myocardial ischaemia; Stroke
- Discontinued Age-related macular degeneration
Most Recent Events
- 30 Sep 2022 Discontinued - Preclinical for Age-related macular degeneration in USA (Intraperitoneal) (InflammX Therapeutics pipeline, September 2022).
- 30 Sep 2022 Preclinical trials in Myocardial ischaemia in USA (Intravitreous) before September 2022
- 30 Sep 2022 Preclinical trials in Stroke in USA (Intravitreous) before September 2022